Illumina ($NASDAQ:ILMN) announced their total revenue for the second quarter of FY2023 as USD 1176.0 million, a 1.2% rise from the prior year’s quarter. Furthermore, their net income for this period was USD -234.0 million, marking an impressive improvement from the -535.0 million reported in the same quarter of FY2022. The report was released on August 9 2023.
Analysis – Illumina Intrinsic Value
GoodWhale has conducted an analysis of ILLUMINA‘s wellbeing and has determined the fair value of ILLUMINA share to be around $284.7, calculated by our proprietary Valuation Line. Currently, ILLUMINA stock is traded at $184.5, which is undervalued by 35.2%. This presents an opportunity for investors to purchase ILLUMINA stock at a discounted price. We believe ILLUMINA is a strong company with great potential and the current stock price discrepancy provides investors with an opportunity to capitalize on this potential. By analyzing ILLUMINA’s financials and current market conditions, we believe investors can benefit from purchasing the stock at its current price and profiting as the stock increases in value to its fair value. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Illumina. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Illumina. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Illumina. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Illumina are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Its products are used by researchers in a variety of fields, including cancer, immunology, and neuroscience. Illumina‘s main competitors are Immunovia AB, Standard BioTools Inc, and BCAL Diagnostics Ltd.
Immunovia is a Swedish company that specializes in the development of blood-based diagnostics for the early detection of cancer. The company was founded in 2003 and has since then developed a number of ground-breaking products, including the world’s first blood test for the early detection of pancreatic cancer. Immunovia’s products are based on cutting-edge technology that allows for the detection of very small changes in the levels of certain proteins in the blood, which can be indicative of the presence of cancer. The company’s flagship product, the PancraFIT test, has been shown to be more than twice as accurate as current standard-of-care tests for pancreatic cancer, and is currently being used in clinical trials in Europe and the United States.
Immunovia’s market cap as of 2022 is 793.92M. The company’s Return on Equity (ROE) for the same year is -27.88%.
– Standard BioTools Inc ($NASDAQ:LAB)
Standard BioTools Inc is a company that manufactures and sells medical devices and equipment. The company has a market capitalization of $89.67 million and a return on equity of 1,331.32%. The company’s products include surgical instruments, medical devices, and laboratory equipment. Standard BioTools Inc is a publicly traded company on the Nasdaq Stock Market under the ticker symbol STBT.
ILLUMINA reported total revenue of USD 1176.0 million for their second quarter of FY2023, indicating a 1.2% increase from the previous year. Net income for the quarter was USD -234.0 million, a drastic improvement from the reported -535.0 million in FY2022 Q2. This positive performance suggests that ILLUMINA is a viable investment opportunity for investors, as the company appears to be experiencing steady growth.
Moreover, the company’s current financial position indicates that they will be able to continue to expand and capitalize on the market in the coming quarters. Thus, investors should consider investing in ILLUMINA as a result of this promising report.